肝特异性钆对比剂钆塞酸二钠给药后脑内钆沉积:与多用途钆对比剂在大鼠中的系统比较
研究将48只Han-Wistar大鼠分为钆塞酸二钠、钆双胺、钆布醇和对照组,经静脉或脑池内给药后5周行脑MRI并定量脑组织钆浓度。结果仅钆双胺组出现齿状核信号增高,钆塞酸二钠脑钆浓度最低,提示其与线性多用途对比剂存在明显差异。
要点
- 仅钆双胺组在盲法阅片可见深部小脑核信号增高,钆塞酸二钠与钆布醇组未见信号改变。
- 静脉给药后小脑钆浓度:钆塞酸二钠0.08 nmol/g,钆双胺2.66 nmol/g,钆布醇0.26 nmol/g。
- 脑池内给药后小脑钆浓度:钆塞酸二钠0.28 nmol/g,钆双胺3.23 nmol/g,钆布醇0.69 nmol/g。
核心结论
- 大鼠研究显示肝特异性线性钆塞酸二钠与多用途线性钆双胺在脑内钆沉积方面存在明显差异;钆塞酸二钠和钆布醇给药后未观察到MRI信号改变,钆塞酸二钠脑钆浓度比钆双胺低一个数量级,略低于钆布醇。
研究设计与样本
- 动物实验:48只Han-Wistar大鼠等分为钆塞酸二钠组、钆双胺组、钆布醇组和对照组(生理盐水或人工脑脊液);每组6只经静脉给药,另6只经脑池内给药,给药5周后行脑MRI并以电感耦合等离子体质谱定量脑组织钆浓度。
关键影像表现/征象
- 盲法阅片仅钆双胺组可见深部小脑核信号增高;深部小脑核与脑干信号强度比值在钆双胺组显著高于对照组(静脉给药P=0.009,脑池内给药P=0.002),钆塞酸二钠和钆布醇组与对照组无差异(P≥0.9)。
诊断标准与关键数值
- 深部小脑核与脑干信号强度比值用于评估信号改变,钆双胺组静脉给药P=0.009、脑池内给药P=0.002,钆塞酸二钠和钆布醇组P≥0.9。
- 静脉给药后小脑钆浓度:钆塞酸二钠0.08 nmol/g、钆双胺2.66 nmol/g、钆布醇0.26 nmol/g。
- 脑池内给药后小脑钆浓度:钆塞酸二钠0.28 nmol/g、钆双胺3.23 nmol/g、钆布醇0.69 nmol/g。
临床应用与阅片要点
- 作者认为钆塞酸二钠与多用途线性钆对比剂脑内钆沉积差异的可能原因包括剂量低4倍、双重排泄途径和络合物稳定性更高;两种给药途径结果相似,支持少量透过血-脑脊液屏障的钆对比剂进一步转运入脑组织的假设。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Clinical studies have reported different results regarding the signal intensity (SI) increase in the dentate nucleus on unenhanced T1-weighted magnetic resonance imaging (MRI) after repeated administrations of gadolinium-based contrast agents (GBCAs). The aim of this study was to evaluate MRI SI changes and gadolinium (Gd) brain concentrations in an animal model after repeated administration of liver-specific linear gadoxetate in comparison to multipurpose linear and macrocyclic GBCAs. Recently, it was demonstrated that small amounts of GBCAs are able to cross the blood-cerebrospinal fluid (CSF) barrier. Therefore, a secondary aim was to test if the administration of these GBCAs directly into the CSF results in a similar MRI pattern and brain Gd concentration than after systemic intravenous injection.
MATERIALS AND METHODS: Forty-eight Han-Wistar rats were equally divided into the following 4 groups: gadoxetate (liver-specific linear), gadodiamide (multipurpose linear), gadobutrol (multipurpose macrocyclic), and control (saline, artificial CSF). For systemic application, 6 animals per group received 8 intravenous injections on 4 consecutive days per week over 2 weeks using a dose of 0.15 mmol/kg for gadoxetate and 0.6 mmol/kg for multipurpose GBCAs per injection, which corresponds to the recommended clinical dose in humans. For CSF application, 6 animals per group received one intracisternal administration of 0.31 μmol Gd (gadoxetate) and 1.25 μmol Gd (multipurpose GBCAs) or an equal volume of artificial CSF. Brain MRI was performed after a period of 5 weeks to evaluate the SI in deep cerebellar nuclei (DCN) and brain stem. Subsequently, animals were euthanized and their brains were dissected for Gd quantification by inductively coupled plasma-mass spectrometry.
RESULTS: Visually evident increased SIs in the DCN were observed in blinded image review only after administration of gadodiamide. The respective SI ratios between DCN and brain stem were significantly higher compared with the control groups (P = 0.009 and P = 0.002 for intravenous and intracisternal application, respectively), whereas no difference was found for gadoxetate and gadobutrol (P ≥ 0.9). Inductively coupled plasma-mass spectrometry revealed the lowest Gd content in the brain tissue after administration for gadoxetate. The mean Gd concentrations in the cerebellum were 0.08 nmol/g (gadoxetate), 2.66 nmol/g (gadodiamide), and 0.26 nmol/g (gadobutrol) after intravenous administration, and 0.28 nmol/g (gadoxetate), 3.23 nmol/g (gadodiamide), and 0.69 nmol/g (gadobutrol) after intracisternal application.
CONCLUSIONS: This rat study demonstrates distinct differences in the presence of gadolinium in the brain between the liver-specific linear gadoxetate and the multipurpose linear GBCA gadodiamide. No MRI signal alterations were observed after 8 dose-adapted intravenous or a single intracisternal administrations of gadoxetate and multipurpose macrocyclic gadobutrol. The Gd concentrations in the brain 5 weeks after intravenous administration of gadoxetate were an order of magnitude lower compared with gadodiamide and slightly lower than for gadobutrol. Likely reasons for these differences are the 4-fold lower dose, the dual excretion pathway, and the higher complex stability of gadoxetate compared with multipurpose linear GBCAs. The similar findings for both routes of GBCA administration underlines the assumption that the very small amount of GBCAs that cross the blood-CSF barrier is further transported into the brain tissue.
引用
- Jost G, Frenzel T, Boyken J, et al. Gadolinium Presence in the Brain After Administration of the Liver-Specific Gadolinium-Based Contrast Agent Gadoxetate: A Systematic Comparison to Multipurpose Agents in Rats. Invest Radiol. 2019. PMID: 30932931. doi:10.1097/RLI.0000000000000559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。